Search Results - "Cazzaniga, M.E"

1872 Moving beyond clinical trials: A real word multicenter Italian experience with albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer by Palumbo, R, Cazzaniga, M.E, Simoncini, E, Tondini, C, Piazza, E, Ferzi, A, Grasso, D, Danova, M, Tarenzi, E, Bernardo, A

Get full text

248 Long Term Treatment with an All-oral Metronomic Schedule of Vinorelbine (VRL) and Capecitabine (CAPE) in Metastatic Breast Cancer (BC) Patients (pts). Preliminary Results of Toxicity and Efficacy of the VICTOR-2 Study by Cazzaniga, M.E, Villa, F, Torri, V, Giuntini, N, Cortinovis, D

Get full text

Metronomic treatment with 5-fluorouracil plus vinorelbine inhibits the expression of markers of stemness in stabilized and primary cell lines of triple-negative breast cancer by Ilari, A., Sherif, N., Grassilli, E., Silva, M., Lavitrano, M., Cazzaniga, M.E., Cerrito, M.G.

Get full text

Metronomic treatment significantly enhanced cytotoxicity in palbociclib-resistant ER-positive breast cancer cell lines by Sherif, N., Ilari, A., Cordani, N., Grassilli, E., Cazzaniga, M.E., Lavitrano, M., Cerrito, M.G.

Get full text

1983P Metronomic combination of 5-fluorouracil plus vinorelbine limits endothelial and triple-negative breast cancer cells proliferation and migration and abolishes clonogenic survival by Cerrito, M.G., Scagliotti, A., Grassilli, E., Lavitrano, M., Cazzaniga, M.E.

Get full text

417P New insights into second-line (2L) choices after CDK4/6 inhibitors (CDK4/6i) in hormone receptor-positive (HR+)/ human epidermal growth factor 2-negative (HER2-) metastatic breast cancer (MBC) patients (pts): Preliminary results of the HERMIONE-13 study by Cogliati, V., Rossi, E., Turla, A., Ambroggi, M., Berardi, R., Borella, F., Coltelli, L., De Giorgi, U.F.F., Ferro, A., Garrone, O., Giordano, M., Landucci, E., Mazzotta, M., Moretti, G., Palumbo, R., Vici, P., Zustovich, F., Riva, F., Capici, S., Cazzaniga, M.E.

Get full text

The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation by Scagliotti, A., Grassilli, E., Cazzaniga, M.E., Capizzi, L., Lavitrano, M., Cerrito, M.G.

Get full text

T.08.1 CHARACTERISTICS AND PREDICTORS OF LIVER TOXICITY IN ADVANCED BREAST CANCER PATIENTS TREATED WITH CYCLINDEPENDENT KINASE INHIBITORS: AN OBSERVATIONAL STUDY by Ciaccio, A., Scaravaglio, M., Laffusa, A., Lucà, M., Longo, S., Manna, M., Maggioni, C., Riva, F., Cicchiello, F., Cazzaniga, M.E., Cortinovis, D.L., Invernizzi, P.

Get full text

2075 POSTER Does the estrogen receptor status influence survival of pCR breast cancer (BC) patients (pts) after primary chemotherapy (CHT)? Results of a multicenter study by Cazzaniga, M.E, Ionta, M.T, Barni, S, Barca, M, Eltrudis, F, Petrelli, F, Trogu, A, Guerzoni, D, Minerba, L, Massidda, B

Get full text

158TiP BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib + letrozole and on second-line treatment with alpelisib + fulvestrant by Allegrini, G., Orditura, M., Del Mastro, L., Zamagni, C., Torrisi, R., Guarneri, V., Paris, I., Sarobba, G., Puglisi, F., Colleoni, M.A., Montemurro, F., Zambelli, A., Cazzaniga, M.E., Valerio, M.R., Bianchi, G., Romagnoli, E., Caruso, M., Cinieri, S., Castelletti, D., Arpino, G.

Get full text

290P From the CLEOPATRA study to real life: Final results from the G.O.N.O. SUPER trial by Garrone, O., Giarratano, T., Michelotti, A., Saggia, C., D'Onofrio, L., Merlini, L., Blondeaux, E., Beano, A., Coltelli, L., Cazzaniga, M.E., Montemurro, F., Farnesi, A., La Verde, N.M., Vandone, A.M., Collovà, E., Blasi, L., Ardito, R., DeConciliis, E., Airoldi, M., Merlano, M.C.

Get full text

P338 - The global care of young women with breast cancer: take care from cure to care. A multidisciplinary educational initiative by Cazzaniga, M.E., Lania, A., Destro, M., Bandera, M., Biasi, G., Giordano, M., Pagani, O.

Get full text

The global care of young women with breast cancer: take care from cure to care. A multidisciplinary educational initiative by Cazzaniga, M.E., Lania, A., Destro, M., Bandera, M., Biasi, G., Giordano, M., Pagani, O.

Get full text

203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer by Cazzaniga, M.E., Martinez Jañez, N., Kukielka-Budny, B.D., Ulanska, M., Bourgeois, H., Muñoz Mateu, M., Morales Murillo, S., Bayo, J., Cortesi, L., Pinter, T., Palacova, M., Cherciu, N., Petru, E., Ettl, J., De Almeida, C., Raymond, R., Villanova, G.R., Thanh Minh, C. Ta, Rodrigues, A.C.F., Freyer, G.

Get full text

292P Serum thymidine kinase 1 activity in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first-line with ribociclib (R) and letrozole (L) in the BioItaLEE trial by Malorni, L., De Laurentiis, M., Bianchini, G., Zambelli, A., Puglisi, F., Bianchi, G.V., Del Mastro, L., Paris, I., Montemurro, F., Allegrini, G., Colleoni, M.A., Tamberi, S., Zamagni, C., Cazzaniga, M.E., Orditura, M., Guarneri, V., Castelletti, D., Benelli, M., Di Marino, M., Arpino, G.

Get full text

Subcutaneous Trastuzumab (scT) and metronomic oral Vinorelbine (mVRL) combination in HER2 + ve advanced breast cancer (ABC) patients (pts): a pilot evaluation of toxicity. Preliminary results of the VICTOR-4 study by Cicchiello, F., Riva, F., Cazzaniga, M.E., Digiacomo, N., Pelizzoni, D., Longarini, R., Capici, S., Bidoli, P.

Get full text

325P - Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study by Cazzaniga, M.E., Pronzato, P., Del Mastro, L., Natoli, C., Montemurro, F., Bisagni, G., Blasi, L., Turletti, A., Giordano, M., Biganzoli, L., Michelotti, A., Garrone, O., Marchetti, P., Riccardi, F., Bernardo, A., Livi, L., Cognetti, F., Donadio, M., Romagnoli, E., Mustacchi, G.

“…Tumor phenotype may change during breast cancer (BC) progression and discordance between primary and metastases ranges between 16% and 21% for Hormone Receptor…”
Get full text

Changes in hormone-receptor status in luminal breast cancers between primary tumour and metastases: Results of the observational cohort GIM-13 AMBRA study by Cazzaniga, M.E., Pronzato, P., Del Mastro, L., Natoli, C., Montemurro, F., Bisagni, G., Blasi, L., Turletti, A., Giordano, M., Biganzoli, L., Michelotti, A., Garrone, O., Marchetti, P., Riccardi, F., Bernardo, A., Livi, L., Cognetti, F., Donadio, M., Romagnoli, E., Mustacchi, G.

Get full text

11P BioItaLEE: Comparative biomarker analysis of liquid biopsies and paired tissue samples of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) by Bianchini, G., De Laurentiis, M., Arpino, G., Zambelli, A., Puglisi, F., Del Mastro, L., Colleoni, M.A., Montemurro, F., Bianchi, G.V., Paris, I., Allegrini, G., Amaducci, L., Cazzaniga, M.E., Orditura, M., Zamagni, C., Bianchetti, S., Castelletti, D., Benelli, M., Callari, M., Malorni, L.

Get full text

Albumin-bounded Paclitaxel (nab-Paclitaxel) in metastatic breast cancer: new insights from a real life multicenter Italian experience by Palumbo, R., Cazzaniga, M.E., Simoncini, E., Tondini, C., Piazza, E., Ferzi, A., Grasso, D., Danova, M., Tarenzi, E., Bernardo, A.

Get full text